HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

Authors

  • Sara E. Khalifa Pathology Department, Faculty of Medicine, Cairo University, Cairo
  • Yasmine Fathy Pathology Department, Faculty of Medicine, Cairo University, Cairo

DOI:

https://doi.org/10.3889/oamjms.2018.318

Keywords:

HER-2, Bone sarcomas

Abstract

BACKGROUND: Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results have been debatable. The her-2 expression is possibly a predictor of chemotherapy response.

AIM: In this study, we investigated the extent of HER-2 expression in bone sarcomas, and attempted to correlate it with pertinent variables that will help to provide better treatment options, especially for metastatic ones.

MATERIAL AND METHODS: Fifty-two cases of bone sarcomas (32 osteosarcoma cases and 20 chondrosarcoma ones) were studied for HER-2 immunohistochemical expression then correlation with all available clinicopathologic features was done.

RESULTS: Most of the osteosarcoma cases exhibited membranous staining (78.1%). Strong staining was observed (score 3+) in 34.4%; while 21.9% showed moderate staining (score 2+); and 21.9% displayed weak staining (score 1+), on the other hand, no staining was detected in 7 out of 32 cases (21.9%) (score 0). As regards chondrosarcoma, the absence of staining in all examined cases was noted. Immunohistochemical HER-2 overexpression correlated significantly with osteosarcoma site with P value = 0.004, with variation relating HER-2 intensity score to the site of osteosarcoma (P = 0.051). A statistically significant negative correlation was detected between HER-2 expression and the presence of metastasis at time of diagnosis (P = 0.006), A significant correlation was also found regarding HER-2 score and presence of metastasis with P value = 0.046 as more than half of cases with no metastasis at diagnosis (17/28 cases, 60.7%) showed positive intensity score. A statistically significant correlation was detected between HER-2 expression and patients’ age (P = 0.044). Also, HER-2 expression significantly correlated to histopathological detection of fibrous tissue, with P value = 0.033. Higher scores of HER-2 expression were associated with a significantly better differentiation (P = 0.038) since detection of wide areas of osteoid were associated with higher HER-2 scores.

CONCLUSION: Further research would still be needed to delineate HER-2 role being a new hope for therapeutic targeting in bone sarcoma patients, mainly osteosarcoma in contrast to chondrosarcoma that didn’t express HER-2 at all.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

von Eisenhart-Rothe R, Toepfer A, Salzmann M, et al.: Primary malignant bone tumours. Orthopade. 2011; 40(12):1121-42. https://doi.org/10.1007/s00132-011-1866-7 PMid:22130624

Campanacci M., Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. Berlin: Springer, 2013: 455-555.

Sissons HA. The WHO classification of bone tumors. Recent Res Cancer Res. 1976; 54:104–108. https://doi.org/10.1007/978-3-642-80997-2_8

Menendez LR. OKU, orthopaedic knowledge update. Rosemont: American Academy of Orthopaedic Surgeons, 2002.

Gill J, Ahluwalia MK, Geller D, Gorlic R. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013; 137:89–99. https://doi.org/10.1016/j.pharmthera.2012.09.003 PMid:22983152

Meazza C and Scanagatta P, Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016; 16(5):543-56. https://doi.org/10.1586/14737140.2016.1168697 PMid:26999418

Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the her-2/neu oncogene. Science. 1987; 235:177–182. https://doi.org/10.1126/science.3798106 PMid:3798106

Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. JBJS. 2009; 91(5):1063-72. https://doi.org/10.2106/JBJS.H.00416 PMid:19411454

Gelderblom H, Hogendoorn PC, Dijkstra SD, et al.; The clinical approach towards chondrosarcoma. Oncologist. 2008; 13:320–29. https://doi.org/10.1634/theoncologist.2007-0237 PMid:18378543

Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Medical science monitor: international medical journal of experimental and clinical research. 2011; 17(8):RA177. https://doi.org/10.12659/MSM.881893 PMid:21804475 PMCid:PMC3539609

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in her2-positive breast cancer. N Engl J Med. 2011; 365:1273–1283. https://doi.org/10.1056/NEJMoa0910383 PMid:21991949 PMCid:PMC3268553

Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression. Mol Ther. 2009; 17:1779–87. https://doi.org/10.1038/mt.2009.133 PMid:19532139 PMCid:PMC2835000

Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64:2047–53. https://doi.org/10.1158/0008-5472.CAN-03-3096 PMid:15026342

Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, Jasiński W, Kawecki K, Wojtacki J. Expression of HER2 in colorectal cancer does not correlate with prognosis. Disease markers. 2010; 29(5):207-12. https://doi.org/10.1155/2010/109063 PMid:21206005

Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer. 2005; 41:1349-1361. https://doi.org/10.1016/j.ejca.2005.03.015 PMid:15913990

Izycka-Swieszewska E, Wozniak A, Drozynska E, Kot J, Grajkowska W, Klepacka T, Perek D, Koltan S, Bien E, Limon J. Expression and significance of HER family receptors in neuroblastic tumors. Clinical & experimental metastasis. 2011; 28(3):271-82. https://doi.org/10.1007/s10585-010-9369-1 PMid:21203803

Nelson EL. HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology Clin. Invest. 2014; 4(8):705–728. https://doi.org/10.4155/cli.14.62

Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Expression of HER2/erb B-2 correlates with survival in osteosarcoma. Journal of Clinical Oncology. 1999; 17(9):2781. https://doi.org/10.1200/JCO.1999.17.9.2781 PMid:10561353

Onda M, Matsuda S, Higaki S, et al: ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996; 77:71-78. https://doi.org/10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5

Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, Fan Q, Qiu X. The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncology letters. 2012; 3(4):797-801. PMid:22740996 PMCid:PMC3362375

Ebb D, Meyers P, Grier H, et al. Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. J Clin Oncol. 2012; 30:2545-2551. https://doi.org/10.1200/JCO.2011.37.4546 PMid:22665540 PMCid:PMC3397787

Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clinical cancer research. 2002; 8(3):788-93. PMid:11895910

Kilpatrick SE, Geisinger KR, King TS, et al. Clinicopathologic Analysis of HER-2/neu Immunoexpression among Various Histologic Subtypes and Grades of Osteosarcoma. Mod Pathol. 2001; 14(12):1277–1283. https://doi.org/10.1038/modpathol.3880474 PMid:11743051

Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. Journal of pediatric hematology/oncology. 2003; 25(1):27-32. https://doi.org/10.1097/00043426-200301000-00007 PMid:12544770

Khalifa SE, Khairy RA, Ramadan R. FGFR3, a marker suggestive of favorable prognosis in urothelial carcinoma. Comparative Clinical Pathology. 2017; 26(5):1203-8. https://doi.org/10.1007/s00580-017-2510-7

Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994; 54:2771–2777. PMid:7909495

Akatsuka T, Wada T, Kokai Y, Sawada N, Yamawaki S, Ishii S. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology. 2001; 60(4):361-6. https://doi.org/10.1159/000058533 PMid:11408805

Li YG, Geng X. A metaâ€analysis on the association of HERâ€2 overexpression with prognosis in human osteosarcoma. European journal of cancer care. 2010; 19(3):313-6. https://doi.org/10.1111/j.1365-2354.2008.00970.x PMid:19709164

Park HR, Kim YW, Jung WW, Kim HS, Unni KK, Park YK. Evaluation of HER-2/neu status by real-time quantitative PCR in malignant cartilaginous tumors. International journal of oncology. 2004; 24(3):575-80. https://doi.org/10.3892/ijo.24.3.575

Published

2018-09-04

How to Cite

1.
Khalifa SE, Fathy Y. HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients. Open Access Maced J Med Sci [Internet]. 2018 Sep. 4 [cited 2024 Mar. 29];6(9):1555-60. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2018.318

Issue

Section

A - Basic Science